- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1129-2377
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies ; volume:21 ; number:1 ; day:16 ; month:3 ; year:2020 ; pages:1-2 ; date:12.2020
The journal of headache and pain ; 21, Heft 1 (16.3.2020), 1-2, 12.2020
- Urheber
-
Haanes, Kristian Agmund
Edvinsson, Lars
Sams, Anette
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s10194-020-01097-3
- URN
-
urn:nbn:de:101:1-2020052920173919927766
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 08:47 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Haanes, Kristian Agmund
- Edvinsson, Lars
- Sams, Anette
- SpringerLink (Online service)
Ähnliche Objekte (12)
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats
Anti-CGRP in cluster headache therapy: a response
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Inflammatory complications of CGRP monoclonal antibodies: a case series
Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
Effectiveness of CGRP (-Receptor) monoclonal antibodies after treatment re-initiation
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats
Anti-CGRP in cluster headache therapy: a response
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Inflammatory complications of CGRP monoclonal antibodies: a case series
Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
Effectiveness of CGRP (-Receptor) monoclonal antibodies after treatment re-initiation
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats
Anti-CGRP in cluster headache therapy: a response
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Inflammatory complications of CGRP monoclonal antibodies: a case series
Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
Effectiveness of CGRP (-Receptor) monoclonal antibodies after treatment re-initiation